Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C0549523
Disease: Oropharynx (excludes nasopharynx)
Oropharynx (excludes nasopharynx)
0.100 Biomarker BEFREE Primary tumor sites included larynx/hypopharynx (27), p16 negative oropharynx (10), and oral cavity (1). 31595355

2019

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C0549523
Disease: Oropharynx (excludes nasopharynx)
Oropharynx (excludes nasopharynx)
0.100 Biomarker BEFREE HPV detection was done on 99 cases from the lip (29), tongue (38) and oropharynx (32) diagnosed at the Pathology Department of the National Cancer Institute, Cairo University. p16 immunohistochemistry was performed on all cases, followed by HPV DNA in situ hybridization (ISH) for p16-positive cases. 30867228

2019

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C0549523
Disease: Oropharynx (excludes nasopharynx)
Oropharynx (excludes nasopharynx)
0.100 Biomarker BEFREE Age, smoking, N3 disease, T4 disease, and a negative p16 status were associated with the development of distant metastases in patients with squamous cell cancers of the oropharynx treated definitively with concurrent chemoradiation. 30548235

2019

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C0549523
Disease: Oropharynx (excludes nasopharynx)
Oropharynx (excludes nasopharynx)
0.100 Biomarker BEFREE While p16 immunohistochemistry (IHC) is typically used as a surrogate for HR-HPV status in the oropharynx and cervix, its overexpression can also occur as a result of oncogenic stress and sometimes prove nonspecific. 31091204

2019

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C0549523
Disease: Oropharynx (excludes nasopharynx)
Oropharynx (excludes nasopharynx)
0.100 Biomarker BEFREE These benefits were observed regardless of p16 status for oropharynx carcinomas. 29878867

2018

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C0549523
Disease: Oropharynx (excludes nasopharynx)
Oropharynx (excludes nasopharynx)
0.100 Biomarker BEFREE As illustrated in this case, immunohistochemistry of the FNAC specimen for p16 was successful in determining the thyroid tumor as a metastatic lesion from the oropharynx. 29445071

2018

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C0549523
Disease: Oropharynx (excludes nasopharynx)
Oropharynx (excludes nasopharynx)
0.100 AlteredExpression BEFREE Patients with oropharynx tumors expressing significant p16 levels (p16-sg) had a 5-year overall survival of 85% compared to 43% for patients with no significant p16 (p16-ns) expression (HR: 0.3 - 95% CI: 0.1-0.6). 29493423

2018

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C0549523
Disease: Oropharynx (excludes nasopharynx)
Oropharynx (excludes nasopharynx)
0.100 Biomarker BEFREE RPPA data suggest high p16 protein expression in many HPV (-) non-oropharyngeal HNSCCs, limiting its potential utility as an HPV biomarker outside of the oropharynx. 30098776

2018

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C0549523
Disease: Oropharynx (excludes nasopharynx)
Oropharynx (excludes nasopharynx)
0.100 Biomarker BEFREE In a subset of 162 patients with both HPV serology and p16 immunohistochemical (IHC) measures available, both measures were similarly associated with survival in the oropharynx (HR for serology, 0.16; 95% CI, 0.03-0.47; for p16 measures, 0.16; 95% CI, 0.03-0.46), whereas only serology was associated with outcome when considering all head and neck cancer cases (HR for serology,0.49; 95% CI, 0.23-1.04; for p16, 0.65; 95% CI, 0.30-1.42). 27930753

2017

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C0549523
Disease: Oropharynx (excludes nasopharynx)
Oropharynx (excludes nasopharynx)
0.100 Biomarker BEFREE HPV-AF estimates based on positivity for HPV-DNA, and for either HPV E6*I mRNA or p16(INK4a), were 22.4%, 4.4%, and 3.5% for cancers of the oropharynx, OC, and larynx, respectively, and 18.5%, 3.0%, and 1.5% when requiring simultaneous positivity for all three markers.HPV16 was largely the most common type. 26823521

2016

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C0549523
Disease: Oropharynx (excludes nasopharynx)
Oropharynx (excludes nasopharynx)
0.100 AlteredExpression BEFREE We then considered 3 cutoffs (10%, 50% and 70% positive cells) to evaluate the outcome of OTs/non-OTs with similar p16 expression and p16-positive versus p16-negative tumors stratified by patient age. 26481441

2016

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C0549523
Disease: Oropharynx (excludes nasopharynx)
Oropharynx (excludes nasopharynx)
0.100 AlteredExpression BEFREE HPV E7 seropositivity correlated with positive tumor HPV-DNA and p16 expression, and was strongly associated with cancers of the oropharynx. 26116154

2015

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C0549523
Disease: Oropharynx (excludes nasopharynx)
Oropharynx (excludes nasopharynx)
0.100 Biomarker BEFREE Among those HNSCCs that were positive for HR-HPV, 18 (100%) of 18 originated from the oropharynx, whereas only two (13%) of 15 HR-HPV-negative HNSCCs originated from the oropharynx (χ(2) test, P < .05). p16 immunohistochemical assay and HPV 16 in situ hybridization on corresponding histologic specimens were concordant with cytologic HR-HPV results. 25873503

2015

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C0549523
Disease: Oropharynx (excludes nasopharynx)
Oropharynx (excludes nasopharynx)
0.100 AlteredExpression BEFREE We evaluated means of p16 and HPV diagnostics, and quantified overexpression of p16 in HPV-positive and -negative OP-SCCs by mode of immunohistochemical staining of carcinoma cells. 24518594

2014

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C0549523
Disease: Oropharynx (excludes nasopharynx)
Oropharynx (excludes nasopharynx)
0.100 Biomarker BEFREE Keratinizing-type squamous cell carcinoma of the oropharynx: p16 overexpression is associated with positive high-risk HPV status and improved survival. 24698966

2014

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C0549523
Disease: Oropharynx (excludes nasopharynx)
Oropharynx (excludes nasopharynx)
0.100 Biomarker BEFREE Human papillomavirus (HPV) infection in squamous cell carcinomas arising from the oropharynx: detection of HPV DNA and p16 immunohistochemistry as diagnostic and prognostic indicators--a pilot study. 25035216

2014

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C0549523
Disease: Oropharynx (excludes nasopharynx)
Oropharynx (excludes nasopharynx)
0.100 AlteredExpression BEFREE No association between KRAS-variant status and p16 expression was observed in the oropharynx subset (Fisher's exact test, P = 1.0). 25081901

2014

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C0549523
Disease: Oropharynx (excludes nasopharynx)
Oropharynx (excludes nasopharynx)
0.100 AlteredExpression BEFREE We immunohistochemically analyzed p16 expression in surgically resected aggressive cutaneous head and neck SCC primaries and their nodal metastases from 24 patients to determine the potential overlap of p16 expression outside of the oropharynx. 23108906

2013

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C0549523
Disease: Oropharynx (excludes nasopharynx)
Oropharynx (excludes nasopharynx)
0.100 Biomarker BEFREE The probability of these cases of metastatic SCC to originate from the oropharynx was assessed by characterizing their morphology (keratinizing vs. nonkeratinizing) and HPV status by in situ hybridization and p16 immunostaining. 22252715

2012

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C0549523
Disease: Oropharynx (excludes nasopharynx)
Oropharynx (excludes nasopharynx)
0.100 AlteredExpression BEFREE The E6/E7 mRNA method confirmed the presence of transcriptionally active HPV-related HNSCC that has a strong predilection for the oropharynx and is strongly associated with high levels of p16 expression. 23060353

2012

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C0549523
Disease: Oropharynx (excludes nasopharynx)
Oropharynx (excludes nasopharynx)
0.100 Biomarker BEFREE We hypothesised p16 staining that considered nuclear localisation might be informative for predicting outcomes in a broader set of HNSCC tumours not limited to the oropharynx, human papilloma virus (HPV) status or by smoking status. 22735904

2012

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C0549523
Disease: Oropharynx (excludes nasopharynx)
Oropharynx (excludes nasopharynx)
0.100 Biomarker BEFREE There was a significant relationship between strong HPV signal and p16(INK4a) staining as well as oropharynx location. 19427557

2009

Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
CUI: C0549523
Disease: Oropharynx (excludes nasopharynx)
Oropharynx (excludes nasopharynx)
0.100 AlteredExpression BEFREE Different studies revealed that: (i) 15-25% of head and neck squamous cell carcinomas (HNSCCs) are clonally associated with high risk HPV types (type 16); (ii) the oropharynx and particularly the tonsils are the most susceptible sites; (iii) patients with HPV-positive tumours present with more advanced stages of disease, are relatively younger, do not have extravagant tobacco and alcohol intake and seem to have a better survival; (iv) HPV-positive tumours are characterized by poor differentiation grade and a basaloid appearance; and (v) HPV-positive tumours exhibit integrated HPV DNA, wild-type p53, pRb downregulation and overexpression of p16INK4A. 15224887

2004